Background: Cardiovascular (CV)-kidney-metabolic (CKM) syndrome, a newly defined entity, offers a framework for assessing CV risk. Emerging evidence suggests that histone deacetylase sirtuin-1 (SIRT1) and adipokine chemerin hold promise as CKM markers. This study aimed to explore the relationship between CKM stage, clinical parameters, and both novel and established markers of CV and renal risk.

Methods: A cohort of 102 patients with long-term, stable kidney transplant (KTx) (>24 months) and median (interquartile range) follow-up of 83 (42-85) months was recruited alongside 32 healthy controls. Patients were classified into modified CKM stages following the American Heart Association guidance. Serum high-sensitivity interleukin-6 (hsIL-6), chemerin, and SIRT1 were measured using commercial immunoassay kits. The incidence of CV events (CVE), CV mortality, and permanent transfer to dialysis therapy were primary endpoints.

Results: CKM stage was associated with higher risk of CVE/CV death (HR 95% CI, 3.79 [1.16-12.42]; P = 0.03) and allograft loss (HR 95% CI, 2.05 [1.17-3.57]; P = 0.01). Elevated sirtuin-1 was associated with significantly lower risk of CV event/death (HR 95% CI, 0.11 [0.11-0.89]; P = 0.04), whereas high chemerin status was tied to dialysis risk (HR 95% CI, 5.77 [1.96-17.00]; P = 0.001) alone. In contrast to sirtuin-1, hsIL-6 and chemerin showed incremental changes across more advanced CKM stages, though statistically significant for hsIL-6 alone. In age-adjusted models for CV disease, independent associations with diabetes and total cholesterol were noted.

Conclusions: Classifying patients based on modified CKM stages offers valuable prognostic insights for stable KTx recipients, particularly when assessing reno-cardiovascular risk. The investigated serum markers may serve as supplemental tools for refining risk stratification.

Download full-text PDF

Source
http://dx.doi.org/10.33963/v.phj.101062DOI Listing

Publication Analysis

Top Keywords

ckm stages
12
ckm
8
ckm syndrome
8
kidney transplant
8
ckm stage
8
modified ckm
8
hsil-6 chemerin
8
risk
7
comprehensive assessment
4
assessment cardiovascular-kidney-metabolic
4

Similar Publications

Background: The triglyceride-glucose (TyG) index has emerged as a credible surrogate indicator of insulin resistance in recent years. This study aimed to investigate the relationship between the TyG index and the deterioration of kidney function in patients with cardiovascular-kidney-metabolic (CKM) syndrome.

Methods: In this retrospective cohort study from China, 27,407 hospitalized patients with stage 1-4 CKM syndrome were consecutively included.

View Article and Find Full Text PDF

Background: Cardiovascular-kidney-metabolic (CKM) syndrome and systemic inflammation significantly contribute to mortality. However, the joint associations of CKM stages and systemic inflammation with all-cause and cardiovascular disease (CVD) mortality remain unclear. This study aimed to evaluate the independent and joint associations of CKM stages and systemic inflammation with all-cause and CVD mortality in a representative cohort of United States adults.

View Article and Find Full Text PDF

The New Cardiovascular-Kidney-Metabolic (CKM) Syndrome: An Opportunity for CKD Detection and Treatment in Primary Care.

Am J Kidney Dis

December 2024

San Francisco VA Health Care System, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Kidney Health Research Collaborative, San Francisco, CA. Electronic address:

In October of 2023, the American Heart Association (AHA) published a scientific statement and advisory that defined a novel entity, the Cardiovascular-Kidney-Metabolic (CKM) Syndrome. The overall framework proposes that a substantial proportion of cardiovascular disease (CVD) burden is attributable to a syndrome that extends in stages from: Stage 1) obesity, Stage 2) metabolic/kidney risk factors for CVD (diabetes mellitus, chronic kidney disease (CKD), hypertension, and dyslipidemia), Stage 3) subclinical CVD, and finally Stage 4) clinical CVD. The report that describes the CKM paradigm documents the scientific justification for a syndrome, highlights the overlap in risk factors among individuals with obesity, diabetes, CKD, and CVD, and aligns the evidence and guideline statements that address screening, prevention, and management of these conditions.

View Article and Find Full Text PDF

An overview of cardiovascular-kidney-metabolic syndrome.

Am J Manag Care

December 2024

Tulane University School of Medicine, 1430 Tulane Ave #8540, New Orleans, LA 70112. Email:

Cardio-kidney-metabolic (CKM) syndrome is a term to describe the interconnection between cardiovascular disease, type 2 diabetes, and chronic kidney disease. The National Health and Nutrition Examination Survey from 1999 to 2020 estimated that 25% of participants had at least 1 CKM condition. It is proposed that CKM syndrome originates in excess and/or dysfunctional adipose tissue, which secretes proinflammatory and prooxidative products leading to damaged tissues in arteries, the heart, and the kidney, and reduction in insulin sensitivity.

View Article and Find Full Text PDF

Background: The American Heart Association recently published guidelines on how to clinically identify and categorize individuals with cardiovascular-kidney-metabolic (CKM) syndrome. The extent to which CKM syndrome prevalence and prognosis differ by sex remains unknown. This study aimed to examine the impact of sex on trends in prevalence over 30 years and the long-term prognosis of CKM syndrome in the United States.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!